Literature DB >> 22310735

Inflammation and fibrogenesis in steatohepatitis.

Hideki Fujii1, Norifumi Kawada.   

Abstract

Nonalcoholic fatty liver disease consists of a range of disorders characterized by excess accumulation of triglyceride within the liver. Whereas simple steatosis is clinically benign, nonalcoholic steatohepatitis (NASH) often progresses to cirrhosis. Inflammation and fibrogenesis are closely inter-related and are major targets of NASH research. Experimental data have shown that inflammation in NASH is caused by insulin resistance, systemic lipotoxicity due to overnutrition, lipid metabolites, the production of proinflammatory cytokines and adipokines by visceral adipose tissue, gut-derived bacteria, and oxidative stress. In NASH-associated fibrosis, the principal cell type responsible for extracellular matrix production is recognized as the hepatic stellate cell. Although the fibrotic mechanisms underlying NASH are largely similar to those observed in other chronic liver diseases, the altered patterns of circulating adipokines, the generation of oxidative stress, and the hormonal profile associated with the metabolic syndrome might play unique roles in the fibrogenesis associated with the disease. Information on the basic pathogenesis of NASH with a focus on the generation of inflammation and fibrosis will be discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310735     DOI: 10.1007/s00535-012-0527-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  146 in total

1.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

2.  Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice.

Authors:  K Tomita; G Tamiya; S Ando; K Ohsumi; T Chiyo; A Mizutani; N Kitamura; K Toda; T Kaneko; Y Horie; J-Y Han; S Kato; M Shimoda; Y Oike; M Tomizawa; S Makino; T Ohkura; H Saito; N Kumagai; H Nagata; H Ishii; T Hibi
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

3.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

Review 4.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

5.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

6.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

7.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

8.  Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Authors:  Luc F Van Gaal; André J Scheen; Aila M Rissanen; Stephan Rössner; Corinne Hanotin; Olivier Ziegler
Journal:  Eur Heart J       Date:  2008-04-15       Impact factor: 29.983

9.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

Review 10.  Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  Expert Opin Emerg Drugs       Date:  2009-03       Impact factor: 4.191

View more
  61 in total

Review 1.  The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.

Authors:  Mithun Sharma; Shasikala Mitnala; Ravi K Vishnubhotla; Rathin Mukherjee; Duvvur N Reddy; Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2015-02-16

2.  Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation.

Authors:  Wen Liang; Jan H Lindeman; Aswin L Menke; Debby P Koonen; Martine Morrison; Louis M Havekes; Anita M van den Hoek; Robert Kleemann
Journal:  Lab Invest       Date:  2014-02-24       Impact factor: 5.662

3.  Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.

Authors:  Varun Chandrashekaran; Suvarthi Das; Ratanesh Kumar Seth; Diptadip Dattaroy; Firas Alhasson; Gregory Michelotti; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Biochim Biophys Acta       Date:  2015-10-22

4.  Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis.

Authors:  Daniel Heinrichs; Marie-Luise Berres; Melanie Coeuru; Meike Knauel; Andreas Nellen; Petra Fischer; Claudia Philippeit; Richard Bucala; Christian Trautwein; Hermann E Wasmuth; Jürgen Bernhagen
Journal:  FASEB J       Date:  2014-08-13       Impact factor: 5.191

5.  GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.

Authors:  Xiao-Min Xin; Mu-Xiao Zhong; Gong-Li Yang; Yao Peng; Ya-Li Zhang; Wei Zhu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 6.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 7.  Vitamin E and nonalcoholic fatty liver disease.

Authors:  Tommy Pacana; Arun J Sanyal
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-11       Impact factor: 4.294

8.  Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH).

Authors:  Ulrike Teufel; Teresa Peccerella; Guido Engelmann; Thomas Bruckner; Christa Flechtenmacher; Gunda Millonig; Felix Stickel; Georg F Hoffmann; Peter Schirmacher; Sebastian Mueller; Helmut Bartsch; Helmut K Seitz
Journal:  Hepatobiliary Surg Nutr       Date:  2015-12       Impact factor: 7.293

9.  Long-term intake of 9-PAHPA or 9-OAHPA modulates favorably the basal metabolism and exerts an insulin sensitizing effect in obesogenic diet-fed mice.

Authors:  Melha Benlebna; Laurence Balas; Béatrice Bonafos; Laurence Pessemesse; Gilles Fouret; Claire Vigor; Sylvie Gaillet; Jacques Grober; Florence Bernex; Jean-François Landrier; Ondrej Kuda; Thierry Durand; Charles Coudray; François Casas; Christine Feillet-Coudray
Journal:  Eur J Nutr       Date:  2020-09-28       Impact factor: 5.614

10.  Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin.

Authors:  Andrew M Shearer; Rajashree Rana; Karyn Austin; James D Baleja; Nga Nguyen; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2016-09-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.